Bacterial pneumonia and pandemic influenza planning
Bacterial pneumonia and pandemic influenza planning
复制标题
DOI：
10.3201/eid1408.070751
复制
发表时间：
2008-08-01
影响因子：
11.8
通讯作者：
Nguyen-Van-Tam, Jonathan S.
中科院分区：
文献类型：
--
作者：
Gupta, Ravindra K.;George, Robert;Nguyen-Van-Tam, Jonathan S.
大流行性流感的规划在全球范围内进行得很好。抗病毒药物和疫苗主导了治疗议程。在储存和规划部署抗菌药以预防继发性细菌性肺炎方面开展的工作要少得多，在以前的大流行和流行病中，继发性细菌性肺炎是导致严重疾病和死亡的原因。一旦发生大流行，有效的抗菌药物措施预计将大大有利于公众健康。我们解决了有关使用抗菌药的问题，因为单个药物的库存减少了，耐药性监测在告知这一政策方面的作用。此外，接种多糖类和结合肺炎球菌疫苗被认为是大流行战略的一部分。大多数流感疾病和死亡可能发生在发展中国家，那里的神经氨酸酶抑制剂和疫苗可能既买不起也买不到；因此，与工业化国家相比，发展中国家治疗细菌并发症的好处可能要大得多。
Pandemic influenza planning is well under way across the globe. Antiviral drugs and vaccines have dominated the therapeutic agenda. Far less work has been conducted on stockpiling and planning for deployment of antimicrobial drugs against secondary bacterial pneumonia, a cause of substantial illness and death in previous pandemics and epidemics. In the event of a pandemic, effective antimicrobial drug measures are expected to substantially benefit public health. We address issues regarding use of antimicrobial drugs as stocks of individual agents are diminished and the role of resistance surveillance in informing such policy. Furthermore, vaccination with polysaccharide and conjugate pneumococcal vaccines is considered as part of a pandemic strategy. Most illness and death from influenza are likely to occur in developing countries, where neuraminidase inhibitors and vaccines may be neither affordable nor available; thus, compared with industrialized countries, the benefits of treating bacterial complications in developing countries may be substantially greater.